SCHEMBL19681264

SCHEMBL19681264

CC(=O)N1CCCC1C(=O)NCCCCC(NC(=O)C1CCCN1C(C)=O)C(=O)NCCCOCCOCCOCCCN

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
APLNR P35414 1/20 0.43
MMP3 P08254 4/20 0.43
MMP1 P03956 1/20 0.43
SIRT6 Q8N6T7 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
NTMT1 Q9BV86 2/20 0.41
F2 P00734 1/20 0.41
ITGB3 P05106 4/20 0.40
ITGA2B P08514 4/20 0.40
NPSR1 Q6W5P4 1/20 0.38
MMP2 P08253 2/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRM1 Q13255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19681253 0.91 SIRT6 (0.52) APLNRMMP3MMP1SIRT6SIRT1
SCHEMBL19681207 0.90 MMP3 (0.46) APLNRMMP3MMP1SIRT6SIRT1
SCHEMBL21166968 0.90 ITGB3 (0.41) POLBTSHRAPLNRNTMT1F2
SCHEMBL21350917 0.89 APLNR (0.40) POLBTSHRAPLNRSIRT6SIRT1
SCHEMBL19677808 0.88 APLNR (0.48) POLBTSHRAPLNRSIRT6SIRT1
SCHEMBL19681206 0.88 TSHR (0.54) POLBTSHRF2NPSR1
SCHEMBL19681283 0.86 APLNR (0.44) APLNRMMP3MMP1SIRT6SIRT1
SCHEMBL21166938 0.84 MMP1 (0.53) APLNRMMP3MMP1NTMT1F2
SCHEMBL19685411 0.84 APLNR (0.48) APLNRMMP3MMP1SIRT6SIRT1
SCHEMBL21351094 0.84 MMP3 (0.46) POLBTSHRAPLNRMMP3MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid ADOCIA (FR) 2023-07-25 US disclosed
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID ADOCIA (FR) 2020-10-01 US disclosed
US-20200046805-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID ADOCIA (FR) 2020-02-13 US disclosed
US-10548952-B2 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2020-02-04 US disclosed
US-10463717-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid ADOCIA (FR) 2019-11-05 US disclosed
US-20190274953-A1 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS ADOCIA (FR) 2019-09-12 US disclosed
US-20190275108-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID ADOCIA (FR) 2019-09-12 US disclosed
US-20190275110-A1 COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID ADOCIA (FR) 2019-09-12 US disclosed
US-10383918-B2 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid ADOCIA (FR) 2019-08-20 US disclosed
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2019-08-20 US disclosed
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID ADOCIA (FR) 2018-07-12 US disclosed
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID ADOCIA (FR) 2017-12-07 US disclosed
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals ADOCIA (FR) 2017-12-07 US disclosed
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid ADOCIA (FR) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190275108-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID IAPP, GPR119, GLP1R POLB 3577/4885TSHR 428/4885APLNR 18/4885
US-20180193421-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID IAPP, GPR119, GIPR POLB 3674/4885TSHR 387/4885APLNR 16/4885
US-10463717-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid IAPP, GPR119, GIPR POLB 3750/4885TSHR 402/4885APLNR 21/4885
US-20200306346-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID GCG, GLP1R, GCGR POLB 4208/4885TSHR 193/4885APLNR 543/4885
US-20200046805-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID IAPP, INSR, GLP1R POLB 3631/4885TSHR 158/4885APLNR 23/4885
US-20170348423-A1 Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR POLB 1545/4885TSHR 984/4885APLNR 1847/4885
US-20170348394-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID GCG, GLP1R, IAPP POLB 3283/4885TSHR 245/4885APLNR 662/4885
US-10383918-B2 Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid GCG, GLP1R, IAPP POLB 3283/4885TSHR 245/4885APLNR 662/4885
US-20190275110-A1 COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID GCG, GLP1R, IAPP POLB 4194/4885TSHR 287/4885APLNR 520/4885
US-20170348395-A1 Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid GCG, GLP1R, IAPP POLB 3326/4885TSHR 202/4885APLNR 671/4885
US-11707507-B2 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid IAPP, INSR, GLP1R POLB 3631/4885TSHR 158/4885APLNR 23/4885
US-10383920-B2 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, IDE, INSR POLB 1881/4885TSHR 1195/4885APLNR 2130/4885
US-20170348396-A1 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, F7, GIPR POLB 2451/4885TSHR 239/4885APLNR 1129/4885
US-20190274953-A1 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS GPR119, INSR, GCG POLB 1994/4885TSHR 605/4885APLNR 389/4885
US-10548952-B2 Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals IAPP, F7, GIPR POLB 2451/4885TSHR 239/4885APLNR 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.